Kraj: Cypr
Język: grecki
Źródło: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
VORICONAZOLE
DELORBIS PHARMACEUTICALS LTD (0000009620) 17 ATHINON STREET, ERGATES INDUSTRIAL AREA, LEFKOSIA, 2081, 28629
J02AC03
VORICONAZOLE
200MG
FILM COATED TABLETS
VORICONAZOLE (8000002580) 200.000000000000MG
ORAL USE
Εθνική Διαδικασία
VORICONAZOLE
Νομικό καθεστώς: Με Ιατρική Συνταγή; PACK WITH 2 TABS IN BLISTER(S) (320018801) 2.00 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 10 TABS IN BLISTER(S) (320018802) 10.00 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 14 TABS IN BLISTER(S) (320018803) 14.00 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 20 TABS IN BLISTER(S) (320018804) 20.00 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 28 TABS IN BLISTER(S) (320018805) 28.00 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 30 TABS IN BLISTER(S) (320018806) 30.00 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 50 TABS IN BLISTER(S) (320018807) 50.00 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 56 TABS IN BLISTER(S) (320018808) 56.00 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή; PACK WITH 100 TABS IN BLISTER(S) (320018809) 100.00 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή
COMPARATIVE TABLE ENGLISH VS GREEK PIL PACKAGE LEAFLET: INFORMATION FOR THE USER CANTEX 50 MG FILM-COATED TABLETS CANTEX 200 MG FILM-COATED TABLETS voriconazole READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Cantex is and what it is used for 2. What you need to know before you take Cantex 3. How to take Cantex 4. Possible side effects 5. How to store Cantex 6. Contents of the pack and other information 1. WHAT CANTEX IS AND WHAT IT IS USED FOR Cantex contains the active substance voriconazole. Cantex is an antifungal ΦΎΛΛΟ ΟΔΗΓΙΏΝ ΧΡΉΣΗΣ: ΠΛΗΡΟΦΟΡΊΕΣ ΓΙΑ ΤΟΝ ΧΡΉΣΤΗ CANTEX 50 MG ΕΠΙΚΑΛΥΜΜΈΝΑ ΜΕ ΛΕΠΤΌ ΥΜΈΝΙΟ ΔΙΣΚΊΑ CANTEX 200 MG ΕΠΙΚΑΛΥΜΜΈΝΑ ΜΕ ΛΕΠΤΌ ΥΜΈΝΙΟ ΔΙΣΚΊΑ βορικοναζόλη ΔΙΑΒΆΣΤΕ ΠΡΟΣΕΚΤΙΚΆ ΟΛΌΚΛΗΡΟ ΤΟ ΦΎΛΛΟ ΟΔΗΓΙΏΝ ΧΡΉΣΗΣ ΠΡΙΝ ΑΡΧΊΣΕΤΕ ΝΑ ΠΑΊΡΝΕΤΕ ΑΥΤΌ ΤΟ ΦΆΡΜΑΚΟ, ΔΙΌΤΙ ΠΕΡΙΛΑΜΒΆΝΕΙ ΣΗΜΑΝΤΙΚΈΣ ΠΛΗΡΟΦΟΡΊΕΣ ΓΙΑ ΣΑΣ. Φυλάξτε αυτό το φύλλο οδηγιών χρήσης. Ίσως χρειαστεί να το διαβάσετε ξανά. Εάν έχετε περαιτέρω απορίες, ρωτήστε τον γιατρό, τον φαρμακοποιό ή τον νοσοκόμο σας. Η συνταγή για αυτό το φάρμακο χορηγήθηκε αποκλειστικά για σας. Δεν π Przeczytaj cały dokument
1. NAME OF THE MEDICINAL PRODUCT Cantex 50 mg Film-coated tablets Cantex 200 mg Film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 50 or 200 mg voriconazole. Excipient(s) with known effect Cantex 50 mg film-coated tablets Each film-coated tablet contains 66.0 mg lactose monohydrate. Cantex 200 mg film-coated tablets Each film-coated tablet contains 264.0 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Cantex 50 mg film-coated tablets White to off-white, round film-coated tablets. Cantex 200 mg film-coated tablets White to off-white, capsule-shaped film-coated tablets. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Cantex is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: Treatment of invasive aspergillosis. Treatment of candidaemia in non-neutropenic patients. Treatment of fluconazole-resistant serious invasive _Candida_ infections (including _C. krusei_). Treatment of serious fungal infections caused by _Scedosporium _spp. and _Fusarium _spp_._ 1 SUMMARY OF PRODUCT CHARACTERISTICS Cantex should be administered primarily to patients with progressive, possibly life-threatening infections. Prophylaxis of invasive fungal infections in high risk allogeneic hepatopoietic stem cell transplant (HSCT) recipients. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy (see section 4.4). Treatment _Adults_ Therapy must be initiated with the specified loading dose regimen of either intravenous or oral voriconazole to achieve plasma concentrations on Day 1 that are close to steady state. On the basis of the high oral bioavailability (96 %; see section 5.2), switching between intravenous and oral administration is appropriate when clinically indicated. Detailed information on dosage Przeczytaj cały dokument